Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jac/dkaa472 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study.
Ann Med
December 2025
Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples "Federico II", Naples, Italy.
Background: Immunocompromised patients are at high risk of developing persisting/prolonged COVID-19. Data on the early combined use of antivirals and monoclonal antibodies in this population are scarce.
Research Design And Methods: We performed an observational, prospective study, enrolling immunocompromised outpatients with mild-to-moderate COVID-19, treated with a combination of sotrovimab plus one antiviral (remdesivir or nirmatrelvir/ritonavir) within 7 days from symptom onset.
Predictive factors associated with short-term mortality in cats with feline infectious peritonitis treated with remdesivir or GS-441524 or both.
J Vet Intern Med
December 2024
Department of Veterinary Medicine, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Hokkaido, Japan.
Background: Although most cats with feline infectious peritonitis (FIP) respond to treatment with remdesivir or GS-441524 or both with uneventful clinical courses, some die despite treatment.
Objective: Identify predictive factors associated with short-term mortality in cats with FIP treated with IV remdesivir or PO GS-441524 or both.
Animals: A total of 108 client-owned cats with FIP.
Clinical Pharmacokinetics and Safety of Remdesivir in Phase I Participants with Varying Degrees of Renal Impairment.
Clin Pharmacokinet
November 2024
Gilead Sciences, Inc., Foster City, CA, 94404, USA.
Background And Objective: Remdesivir is a nucleotide analog prodrug approved for the treatment of COVID-19. This study evaluated the pharmacokinetics and safety of remdesivir and its metabolites (GS-704277 and GS-441524) in participants with varying degrees of renal impairment. Results of this phase I study, along with those of a phase III study, contributed to an extension of indication for remdesivir in the USA and Europe for use in patients with COVID-19 with all stages of renal impairment, including those on dialysis, with no dose adjustment.
View Article and Find Full Text PDFOral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice.
Antimicrob Agents Chemother
October 2024
Department of Medicine, University of California San Diego, La Jolla, California, USA.
Oral broad-spectrum antivirals are urgently needed for the treatment of many emerging and contemporary RNA viruses. We previously synthesized 1--octadecyl-2--benzyl--glyceryl-P-RVn (ODBG-P-RVn, V2043), a phospholipid prodrug of GS-441524 (remdesivir nucleoside, RVn), and demonstrated its efficacy in a SARS-CoV-2 mouse model. Structure-activity relationship studies focusing on the prodrug scaffold identified two modifications, 3-fluoro-4-methoxy-benzyl (V2053) and 4-cyano-benzyl (V2067), that significantly enhanced the broad-spectrum antiviral activity against multiple RNA viruses when compared to V2043.
View Article and Find Full Text PDFA robust mouse model of HPIV-3 infection and efficacy of GS-441524 against virus-induced lung pathology.
Nat Commun
September 2024
KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Virology, Antiviral Drug & Vaccine Research Group, Leuven, Belgium.
Article Synopsis
- HPIV-3 causes serious respiratory infections, and current small-animal models for studying it are inadequate, but AG129 mice effectively replicate the virus's effects.
- Research showed that HPIV-3 targets specific lung cells and leads to significant lung damage, but does not spread between cohabitating infected and non-infected mice.
- Treatment with GS-441524, a remdesivir component, decreased the virus in the lungs and improved lung health, suggesting AG129 mice are useful for testing new treatments and preventative measures for HPIV-3 in humans.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!